Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children

Abstract

Results of this study confirm the safety profile of MFNS in pediatric patients with bilateral nasal polyps over 4 months, even at double the recommended pediatric dosage for allergic rhinitis.

Different types of intranasal steroids for chronic rhinosinusitis

“…Three of the included studies provided a description that suggested that adequate sequence generation was conducted (Chur 2013;Lund 1998;Stjarne 2006). Another three stated that the trials were randomised but did not provide further information, making them at an 'unclear' risk of bias (Filipovic 2006;Holmberg 1997;Johansen 1993).…”

“…However, we only considered the risk of both performance and detection bias to be low for five of the studies, with adequate measures to mask the type of treatment given ( Holmberg 1997;Lund 1998;Small 2005;Stjarne 2006). We rated blinding as inadequate (high risk of bias) in three studies, despite their being reported as 'double-blinded' studies (Chur 2013;Demirel 2008;Johansen 1993). The blinding was inadequate in these studies, as there was no placebo or 'dummy' used to account for differences in the number of times treatment was administered or methods of delivery.…”

“…The risk of attrition bias was unclear in seven of the included studies (Chur 2013;Demirel 2008;Filipovic 2006;Johansen 1993;Small 2005;Stjarne 2006). These studies did not provide enough information to adequately judge the risk.…”

“…We considered only one study to be at low risk of bias, as all expected outcomes were reported (Small 2005). We considered the risk of selective reporting bias to be high in four studies (Chur 2013;Demirel 2008;Holmberg 1997;Lund 1998). Two studies reported the use of diaries for patients to record symptoms (Holmberg 1997; Lund 1998).…”

“…There were five studies, with a total of 663 participants in the intervention arms, which compared a higher dose of intranasal corticosteroids (administered twice a day) versus a lower dose (administered once a day) (Chur 2013;Demirel 2008;Small 2005;Stjarne 2006). One of these was in children aged between 6 and 18 years (Chur 2013). None of the papers provided results for a patient-reported total symptoms score using an instrument validated in a chronic rhinosinusitis population.…”